WorksheetsEvaluate Study Quiz
Total questions: 15
Worksheet time: 30mins
1. What is the primary endpoint of Evaluate Study?
a. Correlation between change in NT-proBNP and remodeling at 12 months
b. Change from baseline to week 12 in aortic characteristic impedance
c. Association between change in NT-proBNP and remodeling at 6 months
d. Change from baseline to week QoL
2. In Evaluate study, Entresto did not reduce the aortic characteristic impedance at week 12 compared to Enalapril
a. True
b. False
3. What is the study design of EVALUATE trial?
a. Randomized, double-blind, double dummy, parallel group, active control
b. Randomized, open-label
c. Randomized, double-blind, parallel group, active-controlled, event-driven
None of the above
4. What is the study duration of Evaluate?
a. 4 weeks
b. 8 weeks
c. 12 weeks
d. 20 weeks
5. How many patients are included in the study?
a. 8442
b. 1002
c. 794
d. 465
6. In Evaluate study, it showed that there is no significant reduction in left ventricular and left atrial volumes vs enalapril?
a. True
b. False
7. In Evaluate study, there is significant reduction in NT-proBNP vs Enalapril.
a. True
b. False
8. In Evaluate study, one of the study limitations is that there is only selected population with mild HF symptoms and no AF
a. True
b. False
9. What is the most common adverse event documented in the Evaluate study?
a. Hypotension
b. Angioedema
c. Hyperkalemia
d. Worsening renal function
10. High aortic characteristic impedance(⬆️Zc) means?
a. Distensible and wide aorta
b. aortic stiffness and ventricular load (Stiff and narrow aorta)
Zinc
Flexible aorta
11. What is the objective of the EVALUATE HF trial?
a. Evaluate the efficacy and safety profile Entresto 200mg BID compared with valsartan 160mg BID in patients with chronic HF and preserved LVEF
b. Evaluate the efficacy and safety profile Entresto 200mg BID comoared with enalapril 10mg BID in patients with chronic HF and reduced LVEF
c. Determine whether treatment of HFrEF with Entresto improves central aortic stiffness and cardiac remodelling compared with enalapril
All of the above
12. What type of patients were included in the EVALUATE-HF Trial?
a. NYHA I-III with LVEF <45%; SBP of >105mmHg
b. NYHA II-IV with LVEF <45%; SBP of >105mmHg
c. NYHA II-III with LVEF >45%; SBP of >105mmHg
d. NYHA II-III with LVEF >35%; SBP of >105mmHg
13. The primary endpoint of EVALUATE HF-Trial is to know the correlation between change in NT-proBNP and remodelling at 12 months
TRUE
FALSE
14.What is the result of the EVALUATE-HF Trial study?
a. 20% reduction in hospital readmission
b. Among patients with HFrEF, Entresto did not reduce Zc at 12 weeks compared with enalapril
c. There was a statistically significant correlation observed between NT pro-BNP and LVEF from baseline to 12 months
b. Among patients with HFrEF, Entresto reduced Zc at 12 weeks compared with enalapril
15. What is the ratio of change in carotid pressure (carotid tonometry) and the change in
flow in the proximal aorta (LVOT doppler)?
a. Ejection Fraction
b. Aortic characteristic impedance (Zc)
c. Heart rate
c. Heart rate
